person · Reporting owner
Nikolopoulos Nicholas J
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avaya Holdings Corp.AVYA · Entity 117306 | SVP Corp Strategy, Dev & Mktng | January 16, 2018 | January 16, 2018 |
| Pediatrix Medical Group, Inc.MD · Entity 4451 | EVP Chf Strategy & Growth Offi | September 15, 2020 | September 17, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avaya Holdings Corp.
Report date January 16, 2018 · Filed January 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $19.46 · Expires 2027-12-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-01-16 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Granted on December 15, 2017 pursuant to the Avaya Holdings Corp. 2017 Equity Incentive Plan (the "EIP"), with 33.33% vesting and becoming exercisable on December 15, 2018 and 8.33% vesting and becoming exercisable on the last day of each quarter thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-01-16 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F3: Each Restricted Stock Unit represents a contingent right to receive, at vesting, one share of common stock of Avaya Holdings Corp. F2: Granted on December 15, 2017 pursuant to the EIP, with 33.33% vesting on December 15, 2018 and 8.33% vesting on the last day of each quarter thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted on December 15, 2017 pursuant to the Avaya Holdings Corp. 2017 Equity Incentive Plan (the "EIP"), with 33.33% vesting and becoming exercisable on December 15, 2018 and 8.33% vesting and becoming exercisable on the last day of each quarter thereafter.
F2: Granted on December 15, 2017 pursuant to the EIP, with 33.33% vesting on December 15, 2018 and 8.33% vesting on the last day of each quarter thereafter.
F3: Each Restricted Stock Unit represents a contingent right to receive, at vesting, one share of common stock of Avaya Holdings Corp.
Pediatrix Medical Group, Inc.
Report date September 15, 2020 · Filed September 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 71,954 |
Reported balance
After 2020-09-15 transaction · row 1
1 source rowRow 1 · 2020-09-15 · Sale · Disposed 10,000 · Balance 71,954 F1: The price reported in Column 4 is a weighted average price. These shares were sold in twenty-four (24) separate transactions with prices ranging from $18.81 to $19.26 for an average weighted sale price of $19.0179. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this section. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in twenty-four (24) separate transactions with prices ranging from $18.81 to $19.26 for an average weighted sale price of $19.0179. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this section.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2020 Filed Sep 17, 2020 21:03 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | SaleCommon Stock | 10,000 | $19.02 | $190,179.00 |
DisclosureSEC source: 0001209191-20-050960 · doc4.xml · nonDerivative · entry 1 Nikolopoulos Nicholas J · CIK 0001722950 · EVP Chf Strategy & Growth Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,954 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in twenty-four (24) separate transactions with prices ranging from $18.81 to $19.26 for an average weighted sale price of $19.0179. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this section. Read SEC document |
| July 12, 2020 Filed Jul 15, 2020 00:20 UTC | Pediatrix Medical Group, Inc. MD · Entity 4451 | Tax withholdingCommon Stock | 53,174 | $17.65 | $938,521.10 |
DisclosureSEC source: 0001209191-20-042451 · doc4.xml · nonDerivative · entry 1 Nikolopoulos Nicholas · CIK 0001722950 · EVP Chf Strategy & Growth Offi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,954 F1 · shares: Represents shares withheld for the payment of taxes upon the vesting of shares of restricted stock previously reported. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.